Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if Flash glucose monitoring system improves glycemic control in adults with new-onset type 2 diabetes
People with new-onset type 2 diabetes who achieve and sustain glycemic targets is important for reducing the risk of complications and all-cause mortality.Glucose monitoring is the key point of diabetes management.Continuous glucose monitoring(CGM)can identify day-to-day glucose profiles to guide management decisions.Flash glucose monitoring is a variant of CGM and is factory calibrated,requiring no finger pricks.The purpose of this study is to determine if Flash glucose monitoring improves glycemic control in adults with new-onset type 2 diabetes.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Flash glucose monitor system(FSL) | Experimental | Except at baseline and at the end of the experiment,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month. |
|
| Self-monitoring blood glucose(SMBG) | No Intervention | People at SMBG group will wear the sensor at baseline and at the end of the experiment for data analysis only,and will have a care visit every month. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Flash Glucose Monitoring System | Device | During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month. |
| Measure | Description | Time Frame |
|---|---|---|
| the between-group difference in mean HbA1c | difference in mean HbA1c between FSL group and SMBG group | 3months |
| Measure | Description | Time Frame |
|---|---|---|
| the between-group difference in mean time in target glucose range | difference in mean time in target glucose range between FSL group and SMBG group | 3months |
| the between-group difference in mean time in hypoglycemia |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yufan Wang, Doctor | Contact | 13761675784 | yyffwangdr@yahoo.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shanghai First People's Hospital | Recruiting | Shanghai | Shanghai Municipality | 200080 | China |
Not provided
This is an open-label, randomized controlled trial. The investigators plan to recruit 200 persons with type 2 diabetes diagnosed within six months. Participants will be randomly assigned (1:1) to either use of a flash glucose monitoring system(FSL) or self-monitoring blood glucose(SMBG) . All participants need to wear the flash glucose monitoring sensor at baseline and at the end of the experiment for data analysis.During the three months of experiment,participants at the FSL group will wear a flash glucose monitoring sensor for 14 days and have a care visit every month,while people at SMBG group will monitor their glucose by pricking a finger at home and receive a care visit every month as well.
The primary outcome is the between-group difference in mean HbA1c at 3 months. Meanwhile,researchers want to know whether differences in glucose variability and diabetes-specific distress between two groups.
Not provided
Not provided
Not provided
Not provided
|
|
difference in mean time in hypoglycemia between FSL group and SMBG group
| 3months |
| the between-group difference in mean time in other biochemical indexes,such as LDL-C,TC,TG and so on | difference in some biochemical indexes between FSL group and SMBG group | 3months |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided